(Q30738659)

26 June 2017

Clinical relevance of brain volume measures in multiple sclerosis (English)

1 reference

26 June 2017

0 references

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24446248%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

Laura Airas

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24446248%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

Jonathan I. O'Riordan

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24446248%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

Finn Sellebjerg

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24446248%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

Heinz Wiendl

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24446248%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

author name string

Nikolaos Grigoriadis

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24446248%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

Heinrich P Mattle

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24446248%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

Celia Oreja-Guevara

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24446248%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

Bruno Stankoff

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24446248%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

Agata Walczak

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24446248%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

Bernd C Kieseier

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24446248%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

publication date

1 February 2014

1 reference

26 June 2017

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24446248%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

volume

28

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24446248%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

issue

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24446248%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

page(s)

147-156

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24446248%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1007/s40263-014-0140-z

1 June 2020

exact match

0 references

1 reference

https://api.crossref.org/works/10.1007%2FS40263-014-0140-Z

Mechanisms of neuronal dysfunction and degeneration in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-014-0140-Z

Factors predisposing to the development of multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-014-0140-Z

Multiple sclerosis - candidate mechanisms underlying CNS atrophy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-014-0140-Z

The immunology of multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-014-0140-Z

Association between pathological and MRI findings in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-014-0140-Z

Preventing brain atrophy should be the gold standard of effective theraphy in MS (after the first year of treatment): No.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-014-0140-Z

Preventing brain atrophy should be the gold standard of effective therapy in MS (after the first year of treatment): Yes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-014-0140-Z

Preventing brain atrophy should be the gold standard of effective therapy in multiple sclerosis (after the first year of treatment): Commentary

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-014-0140-Z

Imaging outcomes for neuroprotection and repair in multiple sclerosis trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-014-0140-Z

Central nervous system atrophy and clinical status in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-014-0140-Z

The measurement and clinical relevance of brain atrophy in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-014-0140-Z

Brain atrophy assessment in multiple sclerosis: importance and limitations

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-014-0140-Z

A new window in multiple sclerosis pathology: non-conventional quantitative magnetic resonance imaging outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-014-0140-Z

Risk factors for progression of brain atrophy in aging: six-year follow-up of normal subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-014-0140-Z

Smoking is associated with increased lesion volumes and brain atrophy in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-014-0140-Z

Reliability of longitudinal brain volume loss measurements between 2 sites in patients with multiple sclerosis: comparison of 7 quantification techniques.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-014-0140-Z

Interferon beta-1a for brain tissue loss in patients at presentation with syndromes suggestive of multiple sclerosis: a randomised, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-014-0140-Z

Long-term effect of early treatment with interferon beta-1b after a first clinical event suggestive of multiple sclerosis: 5-year active treatment extension of the phase 3 BENEFIT trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-014-0140-Z

The effect of interferon beta-1b treatment on MRI measures of cerebral atrophy in secondary progressive multiple sclerosis. European Study Group on Interferon beta-1b in secondary progressive multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-014-0140-Z

Measurement error of two different techniques for brain atrophy assessment in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-014-0140-Z

Effects of early treatment with glatiramer acetate in patients with clinically isolated syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-014-0140-Z

Early brain pseudoatrophy while on natalizumab therapy is due to white matter volume changes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-014-0140-Z

MRI outcomes in a placebo-controlled trial of natalizumab in relapsing MS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-014-0140-Z

Ibudilast in relapsing-remitting multiple sclerosis: a neuroprotectant?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-014-0140-Z

A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-014-0140-Z

Randomized trial of oral teriflunomide for relapsing multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-014-0140-Z

Placebo-controlled trial of oral laquinimod for multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-014-0140-Z

Placebo-controlled trial of oral laquinimod in multiple sclerosis: MRI evidence of an effect on brain tissue damage

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-014-0140-Z

250 microg or 500 microg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-014-0140-Z

Rate of brain atrophy in relapsing MS decreases during treatment with IFNbeta-1a.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-014-0140-Z

The effect of daclizumab on brain atrophy in relapsing-remitting multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-014-0140-Z

Effect of immunomodulatory medication on regional gray matter loss in relapsing-remitting multiple sclerosis--a longitudinal MRI study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-014-0140-Z

Effect of disease-modifying therapies on brain volume in relapsing-remitting multiple sclerosis: results of a five-year brain MRI study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-014-0140-Z

Natalizumab may reduce cognitive changes and brain atrophy rate in relapsing-remitting multiple sclerosis--a prospective, non-randomized pilot study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-014-0140-Z

Alemtuzumab vs. interferon beta-1a in early multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-014-0140-Z

Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-014-0140-Z

Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-014-0140-Z

Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-014-0140-Z

A longitudinal study of brain volume changes in normal aging.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-014-0140-Z

Long-term global and regional brain volume changes following severe traumatic brain injury: a longitudinal study with clinical correlates

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-014-0140-Z

A longitudinal study of brain volume changes in normal aging using serial registered magnetic resonance imaging

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-014-0140-Z

Human brain changes across the life span: a review of 56 longitudinal magnetic resonance imaging studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-014-0140-Z

Assessing brain atrophy rates in a large population of untreated multiple sclerosis subtypes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-014-0140-Z

Gray matter atrophy in multiple sclerosis: a longitudinal study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-014-0140-Z

Brain atrophy in multiple sclerosis: what we know and would like to know

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-014-0140-Z

Magnetization transfer ratio abnormalities reflect clinically relevant grey matter damage in multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-014-0140-Z

MR imaging of multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-014-0140-Z

Thalamic atrophy is associated with development of clinically definite multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-014-0140-Z

Brain atrophy and lesion load predict long term disability in multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-014-0140-Z

Evolution of cortical and thalamus atrophy and disability progression in early relapsing-remitting MS during 5 years

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-014-0140-Z

The relationship between whole brain volume and disability in multiple sclerosis: a comparison of normalized gray vs. white matter with misclassification correction.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-014-0140-Z

Revisiting brain atrophy and its relationship to disability in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-014-0140-Z

Localized grey matter atrophy in multiple sclerosis: a meta-analysis of voxel-based morphometry studies and associations with functional disability.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-014-0140-Z

Eight-year follow-up study of brain atrophy in patients with MS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-014-0140-Z

Progressive ventricular enlargement in patients with clinically isolated syndromes is associated with the early development of multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-014-0140-Z

Two-year follow-up study of primary and transitional progressive multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-014-0140-Z

Magnetic resonance imaging correlates of physical disability in relapse onset multiple sclerosis of long disease duration

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-014-0140-Z

Voxel-wise mapping of cervical cord damage in multiple sclerosis patients with different clinical phenotypes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-014-0140-Z

Relevance of spinal cord abnormalities to clinical disability in multiple sclerosis: MR imaging findings in a large cohort of patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-014-0140-Z

Regional cervical cord atrophy and disability in multiple sclerosis: a voxel-based analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-014-0140-Z

Gray matter atrophy and disability progression in patients with early relapsing-remitting multiple sclerosis: a 5-year longitudinal study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-014-0140-Z

Thalamic damage and long-term progression of disability in multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-014-0140-Z

Gray matter damage predicts the accumulation of disability 13 years later in MS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-014-0140-Z

Information processing speed, neural efficiency, and working memory performance in multiple sclerosis: differential relationships with structural magnetic resonance imaging.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-014-0140-Z

Exploration of the relationships between regional grey matter atrophy and cognition in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-014-0140-Z

Clinical significance of atrophy and white matter mean diffusivity within the thalamus of multiple sclerosis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-014-0140-Z

MRI predictors of cognitive outcome in early multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-014-0140-Z

Cortical pathology and cognitive impairment in multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-014-0140-Z

Regional hippocampal atrophy in multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-014-0140-Z

Cognitive impairment in MS: impact of white matter integrity, gray matter volume, and lesions

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-014-0140-Z

Relevance of brain lesion location to cognition in relapsing multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-014-0140-Z

Lamotrigine for neuroprotection in secondary progressive multiple sclerosis: a randomised, double-blind, placebo-controlled, parallel-group trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-014-0140-Z

Mechanisms of action of disease-modifying agents and brain volume changes in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-014-0140-Z

Rate of brain atrophy in benign vs early multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-014-0140-Z

Association of matrix metalloproteinases with MRI indices of brain ischemia and aging

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-014-0140-Z

Regulation of matrix metalloproteinases and their inhibitors by interferon-beta: a longitudinal study in multiple sclerosis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-014-0140-Z

Midlife vascular risk factor exposure accelerates structural brain aging and cognitive decline.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-014-0140-Z

Brain reserve and cognitive reserve in multiple sclerosis: what you've got and how you use it

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-014-0140-Z

Cognitive reserve and cortical atrophy in multiple sclerosis: a longitudinal study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-014-0140-Z

Sub-threshold cognitive impairment in multiple sclerosis: the association with cognitive reserve.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-014-0140-Z

Active cognitive reserve influences the regional atrophy to cognition link in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-014-0140-Z

Steroids and brain atrophy in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-014-0140-Z

MRI monitoring of immunomodulation in relapse-onset multiple sclerosis trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-014-0140-Z

Clinical impact of early brain atrophy in clinically isolated syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-014-0140-Z

Association of Neocortical Volume Changes With Cognitive Deterioration in Relapsing-Remitting Multiple Sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-014-0140-Z

New approaches in the management of multiple sclerosis

21 January 2018

1 reference

12 December 2020

Detection of ventricular enlargement in patients at the earliest clinical stage of MS

1 reference

12 December 2020

Use of the brain parenchymal fraction to measure whole brain atrophy in relapsing-remitting MS. Multiple Sclerosis Collaborative Research Group

1 reference

12 December 2020

Bimonthly Evolution of Cortical Atrophy in Early Relapsing-Remitting Multiple Sclerosis over 2 Years: A Longitudinal Study.

1 reference

12 December 2020

Neocortical volume decrease in relapsing-remitting MS patients with mild cognitive impairment

1 reference

12 December 2020

Early central atrophy rate predicts 5 year clinical outcome in multiple sclerosis

1 reference

12 December 2020

Brain atrophy in relapsing multiple sclerosis: relationship to relapses, EDSS, and treatment with interferon beta-1a

1 reference

12 December 2020

Gray matter atrophy is related to long-term disability in multiple sclerosis

1 reference

12 December 2020

Predicting short-term disability progression in early multiple sclerosis: added value of MRI parameters

1 reference

12 December 2020

Clinical and magnetic resonance imaging predictors of disease progression in multiple sclerosis: a nine-year follow-up study.

1 reference

12 December 2020

Relationship between brain atrophy and disability: an 8-year follow-up study of multiple sclerosis patients

1 reference

12 December 2020

10.1007/S40263-014-0140-Z

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24446248%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

1 reference